The COVID-19 pandemic created new opportunities for the biotech sector through the increased demand for drugs and vaccines. In the post-pandemic world, personalized medicines and innovative drug formulations are expected to keep the industry buoyed.
Last month, the White House announced its plans to invest more than $2 billion in the U.S. biotechnology sector. The executive order signed by President Biden launched the national biotechnology and bio-manufacturing initiative, which is expected to fund medical breakthroughs.
